797047-10-0

Basic information

• Product Name: 1H-Pyrazole, 1-(5-bromo-3-fluoro-2-nitrophenyl)-
• CAS NO: 797047-10-0
• Molecular Formula: C9H5BrFN3O2
• Molecular Weight: 286.06
• Mol File: 797047-10-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1H-Pyrazole, 1-(5-bromo-3-fluoro-2-nitrophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazole, 1-(5-bromo-3-fluoro-2-nitrophenyl)-(797047-10-0)
• EPA Substance Registry System: 1H-Pyrazole, 1-(5-bromo-3-fluoro-2-nitrophenyl)-(797047-10-0)

Safety Data

• Hazardous Substances Data: 797047-10-0(Hazardous Substances Data)

Upstream product

• 288-13-1 NH-pyrazole 
• 147808-42-2 5-bromo-1,3-difluoro-2-nitro-benzene 

Downstream Products

• 797047-11-1 5-bromo-2-nitro-3-pyrazol-1-ylphenylamine 

Relevant articles and documents

Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: Intelligent design and evolution through the judicious use of structure-guided design and stucture-activity relationships

The discovery of new antibacterial agents with novel mechanisms of action is necessary to overcome the problem of bacterial resistance that affects all currently used classes of antibiotics. Bacterial DNA gyrase and topoisomerase IV are well-characterized clinically validated targets of the fluoroquinolone antibiotics which exert their antibacterial activity through inhibition of the catalytic subunits. Inhibition of these targets through interaction with their ATP sites has been less clinically successful. The discovery and characterization of a new class of low molecular weight, synthetic inhibitors of gyrase and topoisomerase IV that bind to the ATP sites are presented. The benzimidazole ureas are dual targeting inhibitors of both enzymes and possess potent antibacterial activity against a wide spectrum of relevant pathogens responsible for hospital- and community-acquired infections. The discovery and optimization of this novel class of antibacterials by the use of structure-guided design, modeling, and structure-activity relationships are described. Data are presented for enzyme inhibition, antibacterial activity, and in vivo efficacy by oral and intravenous administration in two rodent infection models.

Gyrase inhibitors and uses thereof

The present invention relates to methods of treating, preventing, or lessening the severity of resistant bacterial infections in mammals, utilizing compounds of formula I or formula VII or pharmaceutically salts thereof. The present invention also relates